Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deoxyribonuclease-2-beta (DNASE2B) is a lysosomal endonuclease enzyme that catalyzes the hydrolysis of double-stranded DNA at acidic pH and does not require divalent cations for activity[1][2][6]. It participates in the degradation of nuclear DNA, notably during the differentiation of lens cells in the eye and is mainly expressed in the salivary gland and lungs in humans[1][2][6]. DNASE2B is structurally related to DNASE2, but has a much more restricted tissue expression[1][2][6]. Genetic variants in DNASE2B have been associated with ocular disease, particularly cataract[1]. DNASE2B is part of the DNase2 family of lysosomal enzymes involved in the removal of self-DNA from dying cells and the maintenance of tissue homeostasis[4]. No drugs are currently known to target DNASE2B directly, and its primary characterized function is in physiological DNA clearance rather than pathology or direct therapeutic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deoxyribonuclease-2-beta (DNASE2B).